Today we’re presenting late-breaking results from our Phase 2 AMPLIFY-7P study evaluating camupepimut (ELI-002 7P) in patients with resected pancreatic cancer at #ESMO26, as well a

Elicio Therapeutics· @ElicioTx · X·2026-10-23 21:03· 2 days agoScore70

Body

Today we’re presenting late-breaking results from our Phase 2 AMPLIFY-7P study evaluating camupepimut (ELI-002 7P) in patients with resected pancreatic cancer at #ESMO26, as well as in a Nature Medicine publication. Read more about the study results here: https://bit.ly/4snQBEr

113 views · 1 like · 1 repost · 0 replies

Conference abstracts

7Pmatched by Proffered paper 1: Gastrointestinal tumour, upper digestive

Proffered paper 1: Gastrointestinal tumour, upper digestive

https://esmocongress.esmo.org

Source: Elicio Therapeutics · x.com